01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins for use in the manufacture of food supplements;
chemical additives for vitamins; chemical supplements for
use in the manufacture of vitamins; vitamins for the
manufacture of food supplements; vitamins for use in the
manufacture of pharmaceuticals. Food supplements; nutritional supplements; vitamin
supplements; dietary supplements; vitamin B preparations;
vitamin preparations; dietary supplements consisting of
vitamins; vitamins and vitamin preparations; vitamin
preparations; fertility enhancement preparations.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins used as active ingredients in the manufacture of
pharmaceutical preparations, food preparations, food
supplements. Vitamins; vitamin supplements; dietetic substances composed
of dietetic vitamins for medical and pharmaceutical use;
food supplements; nutritional and dietetic supplements;
bacteria and bacterial preparations for pharmaceutical or
medical use; preparations of probiotics or other nutrients
for human consumption; probiotic composition for human food;
culture of micro-organisms with a probiotic effect on the
human organism, for medical use.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Vitamins for use in the manufacture of food supplements; chemical additives for vitamins; chemical supplements for use in the manufacture of vitamins; vitamins for the manufacture of food supplements; vitamins for use in the manufacture of pharmaceuticals.
(2) Food supplements containing folates for health and general well-being; nutritional supplements containing folates for health and general well-being; vitamin supplements; dietary supplements containing folates for health and general well-being; vitamin B preparations; vitamin preparations; dietary supplements consisting of vitamins; vitamins and vitamin preparations; vitamin preparations; fertility enhancement preparations for human use.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements
(2) Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use namely nutritional yeast and probiotic; food supplements for the overall health and well-being of the body; food supplements based on micro-organisms namely nutritional actives, nutritional yeasts and probiotics for general health and well-being; bacteria and bacterial preparations for pharmaceutical and medical use for the overall health and well-being of the body; preparations of probiotics for human consumption for the overall health and well-being of the body; probiotic composition for human food for medical use; culture of micro-organisms with a probiotic effect on the human organism, for medical use namely yeast.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements, all of the foregoing containing menaquinone-7 in whole or significant part Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; preparations of probiotics for human consumption; nutrients for human consumption being dietary and nutritional supplements; probiotic composition for human food being dietary and nutritional supplements; culture of micro-organisms with a probiotic effect on the human organism, for medical use; all of the foregoing containing menaquinone-7 in whole or significant part
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins used as active ingredients in the manufacture of
pharmaceutical preparations, food preparations, food
supplements. Vitamins; vitamin supplements; dietetic substances composed
of dietetic vitamins for medical and pharmaceutical use;
food supplements; nutritional and dietetic supplements;
bacteria and bacterial preparations for pharmaceutical or
medical use; preparations of probiotics or other nutrients
for human consumption; probiotic composition for human food;
culture of micro-organisms with a probiotic effect on the
human organism, for medical use.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements.
(2) Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use namely nutritional yeast and probiotic; food supplements for the overall health and well-being of the body; food suppléments based on micro-organisms namely nutritional actives, nutritional yeasts and probiotics for general health and well-being; bacteria and bacterial preparations for pharmaceutical and medical use for the overall health and well-being of the body; preparations of probiotics for human consumption for the overall health and well-being of the body; probiotic composition for human food for medical use; culture of micro-organisms with a probiotic effect on the human organism, for medical use namely yeast.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations and food supplements, all of the foregoing containing menaquinone-7 in whole or significant part Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; preparations of probiotics for human consumption; nutrients for human consumption being dietary and nutritional supplements; probiotic composition for human food being dietary and nutritional supplements; culture of micro-organisms with a probiotic effect on the human organism, for medical use; all of the foregoing containing menaquinone-7 in whole or significant part
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements. Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; bacteria and bacterial preparations for pharmaceutical or medical use; preparations of probiotics or other nutrients for human consumption; probiotic composition for human food; culture of micro-organisms with a probiotic effect on the human organism, for medical use.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements. Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; bacteria and bacterial preparations for pharmaceutical or medical use; preparations of probiotics or other nutrients for human consumption; probiotic composition for human food; culture of micro-organisms with a probiotic effect on the human organism, for medical use.
The invention relates to reduced glutathione in a highly water-soluble solid form, the process for the preparation thereof, and pharmaceutical, nutraceutical or veterinary formulations containing it.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
The invention relates to the salt of (SS)-adenosyl methionine with myo-inositol 1,2,3,4,5,6 hexakisphosphate, and pharmaceutical, nutraceutical or veterinary formulations containing it.
A61K 31/6615 - Composés ayant plusieurs groupes d'acide du phosphore estérifiés, p. ex. triphosphate d'inositol, acide phytique
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
18.
PROCESS FOR THE PURIFICATION OF LIPOPOLYPEPTIDE ANTIBIOTICS
Disclosed is a process for the purification of lipopolypeptide antibiotics from culture broths which comprises: a) removal of the mycelium from the broth; b) anion-exchange chromatography of the solution resulting from stage a), eluting with di- or trivalent ions; c) optional concentration of the purified fraction resulting from stage b); d) hydrophobic interaction chromatography of the fraction resulting from stage b) or c), eluting with C1-C4 alcohols; e) cation-exchange chromatography of the desired lipopolypeptide-enriched fraction resulting from stage d), eluting at a pH equal to or greater than the isoelectric point of the lipopolypeptide; f) dialysis, concentration and freeze-drying or spray-drying of the purified lipopolypeptide.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.
C07C 37/07 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone d'un cycle aromatique à six chaînons par conversion de cycles non aromatiques à six chaînons ou de tels cycles formés in situ, en cycles aromatiques à six chaînons, p. ex. par déshydrogénation avec réduction simultanée du groupe C=O de ce cycle
C07C 37/84 - SéparationPurificationStabilisationEmploi d'additifs par traitement physique par cristallisation
C07C 39/225 - Composés comportant au moins un groupe hydroxyle ou O-métal lié à un atome de carbone d'un cycle aromatique à six chaînons polycycliques ne contenant que des cycles aromatiques à six chaînons dans la partie cyclique, avec une insaturation autre que celle des cycles au moins un groupe hydroxyle étant lié à un système cyclique condensé
C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical compositions; pharmaceutical products;
pharmaceutical preparations for veterinary use;
neutraceutical preparations for veterinary and human use;
vitamin supplements; probiotic supplements; homeopathic
supplements; nutritional supplements for medical use;
dietetic supplements for medical use; nutritional
supplements for medical use; mineral supplements for medical
use; feed supplements for veterinary use; dietary
supplemental drinks; food supplements for non-medical
purposes; nutraceuticals for use as a dietary supplement;
vitamin preparations in the nature of food supplements;
dietetic substances for medical use; dietetic food and
preparations for medical use; dietetic substances adapted
for veterinary use.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical compositions namely pharmaceutical compositions for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; pharmaceutical products namely pharmaceutical preparations for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; pharmaceutical preparations for veterinary use for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; nutraceutical preparations for veterinary and human use namely stabilized bulk powder in the form of phytate for use in the manufacture of nutraceuticals; vitamin supplements; probiotic supplements; homeopathic supplements in the form of liquid and caplets, for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; nutritional supplements for medical use namely supplements for the promotion of healthy liver function, for the treatment and prevention of joints pain, mood disorders and for the promotion of the induction of ovulation; dietetic supplements for medical use namely vitamins; mineral supplements for medical use; feed supplements for veterinary use namely animal feed supplements for veterinary purposes; dietary supplemental drinks namely liquid vitamin supplements; food supplements for non-medical purposes namely bee pollen for use as a dietary food supplement; nutraceuticals for use as a dietary supplement namely dietary supplements for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; vitamin preparations in the nature of food supplements namely vitamin and mineral food supplements; dietetic food and preparations for medical use namely dietetic substances consisting of vitamins, minerals, amino acids and trace elements; dietetic substances adapted for veterinary use namely stabilized bulk powder in the form of phytate for use in the manufacture of nutraceuticals for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vitamin supplements; Probiotic supplements; Homeopathic supplements; Nutritional supplements for medical use; Dietetic supplements for medical use, namely, dietary supplements; Mineral supplements for medical use; Animal feed supplements for veterinary use; Dietary supplemental drinks; Food supplements for non-medical purposes; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Dietetic food and preparations being vitamins, capsules and tablets adapted for medical use; Dietetic substances being foods, croquettes and chewable tablets adapted for veterinary use; all of the foregoing goods containing S- Adenosyl methionine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical compositions; Pharmaceuticals; Pharmaceutical preparations for veterinary use; Nutraceutical preparations for human and veterinary use; Vitamin supplements; Probiotic supplements; Homeopathic supplements; Nutritional supplement for medical use; Nutritional supplements; Nutritional supplements; Mineral supplements for medical purposes; Nutritional supplements for veterinary use; Dietary supplemental drinks; Food supplements for non-medical purposes; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Dietetic substances adapted for medical use; Dietetic foodstuffs and substances adapted for medical use; Dietetic substances adapted for veterinary use.
The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.
C07C 37/07 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone d'un cycle aromatique à six chaînons par conversion de cycles non aromatiques à six chaînons ou de tels cycles formés in situ, en cycles aromatiques à six chaînons, p. ex. par déshydrogénation avec réduction simultanée du groupe C=O de ce cycle
C07C 37/84 - SéparationPurificationStabilisationEmploi d'additifs par traitement physique par cristallisation
C07C 39/225 - Composés comportant au moins un groupe hydroxyle ou O-métal lié à un atome de carbone d'un cycle aromatique à six chaînons polycycliques ne contenant que des cycles aromatiques à six chaînons dans la partie cyclique, avec une insaturation autre que celle des cycles au moins un groupe hydroxyle étant lié à un système cyclique condensé
C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
36.
Crystalline forms of s-acetyl glutathione, their preparations and uses in pharmaceutical and nutraceutical formulations
Disclosed are two novel crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallization of SAG from mixtures of water-acetone, water-ethanol or water acetone under controlled conditions. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
C07K 1/30 - ExtractionSéparationPurification par précipitation
A61K 38/00 - Préparations médicinales contenant des peptides
E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them.
This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof.
This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 9/46 - Pilules, pastilles ou comprimés effervescents
The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: c) a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and d) an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: c) a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and d) an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
51.
CRYSTALLINE FORMS OF S-ACETYL GLUTATHIONE, THEIR PREPARATIONS AND USES IN PHARMACEUTICAL AND NUTRACEUTICAL FORMULATIONS
Disclosed are two crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallisation of SAG from mixtures of water-acetone, water-ethanol or water-methanol, preferably acetone, under controlled conditions. The crystalline forms are characterised by X-ray powerder diffrraction, IR spectrum and DSC. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
52.
CRYSTALLINE FORMS OF S-ACETYL GLUTATHIONE, THEIR PREPARATIONS AND USES IN PHARMACEUTICAL AND NUTRACEUTICAL FORMULATIONS
Disclosed are two crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallisation of SAG from mixtures of water-acetone, water-ethanol or water-methanol, preferably acetone, under controlled conditions. The crystalline forms are characterised by X-ray powerder diffrraction, IR spectrum and DSC. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic food and
substances adapted for medical or veterinary use, food for
babies; dietary supplements for humans and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides.
S-adenosyl methionine, and the salts and complexes thereof, in the form of a spray-dried sterile powder which has a pharmacologically active enantiomer content exceeding 70% and a water residue below 2.5% by weight.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
C07C 281/18 - Composés contenant l'un des groupes p. ex. aminoguanidine l'autre atome d'azote étant lié de plus par une liaison double à un atome de carbone, p. ex. guanylhydrazones
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Food and dietetic substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides.
The present invention describes combinations comprising chondroitin sulphate (CS), one or more enzymes or enzymatic mixtures possessing proteolytic activity, and sulphydryl compounds, for the treatment and prevention of osteoarthritis and correlated acute and chronic inflammatory processes, or as nutraceutical compositions for the maintenance of musculoskeletal well-being in humans and animals. The characteristic of said combinations is that they increase the intestinal absorption of CS when administered orally. The effect of said combinations is exerted on a wide range of molecular weights of CS, including CS samples with very low molecular weights which already possess greater bioavailability than samples with a higher molecular weight. The effect is exerted on CS samples of any origin.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
The present invention describes combinations comprising chondroitin sulphate (CS), one or more enzymes or enzymatic mixtures possessing proteolytic activity, and sulphydryl compounds, for the treatment and prevention of osteoarthritis and correlated acute and chronic inflammatory processes, or as nutraceutical compositions for the maintenance of musculoskeletal well-being in humans and animals. The characteristic of said combinations is that they increase the intestinal absorption of CS when administered orally. The effect of said combinations is exerted on a wide range of molecular weights of CS, including CS samples with very low molecular weights which already possess greater bioavailability than samples with a higher molecular weight. The effect is exerted on CS samples of any origin.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
68.
Saccharomyces boulardii and superoxide dismutase (SOD) to control obesity
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
Disclosed is a low-molecular-weight (1000-5000 daltons) chondroitin sulphate (CS) produced by chemical sulphation and subsequent depolymerisation of a non-sulphated chondroitin backbone obtained with biotechnology techniques. The CS described is substantially monosulphated, mainly at the 6-position, with very little sulphation at the 4-position, and with a mono/disulphated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin 6-sulphate (C6S) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Food supplements, herbal supplements, botanicals, botanical extracts, and nutraceuticals for medical or veterinary use for improving metabolism, mood and brain functions, liver health and joint health, and for general health and well-being, food for babies; dietary supplements for humans and animals for improving metabolism, mood and brain functions, liver health and joint health, and for general health and well-being.
74.
Composition comprising shellac and/or a salt thereof and sodium starch glycolate
The object of the present invention is a composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The present invention concerns a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark¬ like chondroitin sulphate, showing a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates; the invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and charge density; its in vitro biological and anti-inflammatory effectiveness, comparable to the ones of natural products make this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.
The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4, or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate.
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
A61K 31/7008 - Composés ayant un groupe amino lié directement à un atome de carbone du radical saccharide, p. ex. D-galactosamine, ranimustine
A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
82.
"BIOTECHNOLOGICAL SULPHATED CHONDROITIN SULPHATE AT POSITION 4 OR 6 ON THE SAME POLYSACCHARIDE CHAIN, AND PROCESS FOR THE PREPARATION THEREOF"
The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4, or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
The object of the present invention is a composition shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.
The object of the present invention is a composition shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible of fructose residues addition to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12P 15/00 - Préparation de composés contenant au moins trois carbocycles condensés
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible of fructose residues addition to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use, food for babies; plasters,
materials for dressings; material for stopping teeth, dental
wax; disinfectants; preparations for destroying vermin;
fungicides, herbicides.
The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
93.
USE OF S-ADENOSYLMETHIONINE (SAM) AND SUPEROXIDE DISMUTASE (SOD) FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
C07D 475/04 - Composés hétérocycliques contenant des systèmes cycliques ptéridine avec un atome d'oxygène lié directement en position 4 avec un atome d'azote lié directement en position 2
95.
PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID
The invention relates to a process for the diastereoisomeric resolution of 5-methyltetrahydrofolic acid; it discloses also a crystalline amine salt of 5-methyltetrahydrofolic acid and is further directed to a process for the transformation of the single diastereoisomers of the 5-methyltetrahydrofolic amine salts obtained by the process of the invention into the corresponding free acid or into an alkaline earth metal salt. The invention provides a simple, economically advantageous and efficient process and allows to obtain stable and pure (6R) and ( 6S) -diastereoisomers of 5-methyltetrahydrofolic acid in a good yield and diastereoisomeric purity.
C07D 475/04 - Composés hétérocycliques contenant des systèmes cycliques ptéridine avec un atome d'oxygène lié directement en position 4 avec un atome d'azote lié directement en position 2
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.
C07D 475/04 - Composés hétérocycliques contenant des systèmes cycliques ptéridine avec un atome d'oxygène lié directement en position 4 avec un atome d'azote lié directement en position 2
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.
The invention relates to pharmaceutical and nutraceutical compositions containing as the active ingredient a menaquinol of formula (I) wherein n is as defined in the description, for the prevention of cardiovascular diseases and bone metabolism disorders.
